Progression of disease and tumor characteristics can help determine how patients should be treated, according to new data. Patients with stage IIIC ovarian cancer and tumors of 45 mm or smaller attained greater benefit at five years from primary surgery, while those with stage IV disease and larger tumors showed better outcomes with neoadjuvant chemotherapy. The results appear in the European Journal of Cancer.

Related Summaries